Home Equities Score Atossa Therapeutics, Inc. (ATOS) stock surged in the premarket trading session; here’s...

Atossa Therapeutics, Inc. (ATOS) stock surged in the premarket trading session; here’s why

In the pre market trading session, Atossa Therapeutics Inc. (ATOS) stock has surged by 7.27% to $2.36 at the time of writing. ATOS stock closed the previous session at $2.20 gaining 12.24%. The ATOS stock volume traded about 20.85 million shares. In the past year, ATOS stock slumped by -0.90%. While in the past week the shares jumped up by 29.41%. In the past three and six months, the ATOS stock slumped-0.90% and added 32.53% respectively. Furthermore, Atossa is currently valued in the market at $265.81 million and the ATOS stock has 120.82 million outstanding shares.

Get the hottest stocks to trade every day before the market opens 100% ‎free. Click here now. 

Atossa Therapeutics, Inc.’s operational background

Atossa Therapeutics, Inc. founded in 2009, is a clinical-stage biopharmaceutical company that specifically focuses on developing and marketing medical devices, laboratory studies, and treatment of patients with breast health issues with therapeutics in the USA. In January 2020, the company changed its name from Atoss Genetics to what it currently is. The company is headquartered in Seattle, Washington.


The 2021 Backdoor Crypto Portfolio (free)

Even if you’re not actively in crypto, you deserve to know what’s actually going on...

Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.

Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free.

Sponsored


Read More

Atossa Therapeutics, Inc.’s development pipeline and clinical trials

Atossa Therapeutics, Inc. is a lead investigational candidate is Endoxifen, which is in developmental Phase II studies to treat and prevent breast cancer. Endoxifen is an active metabolite of tamoxifen. The clinical-stage company is also targeting therapy delivery by developing intraductal microcatheter technology. This technology also includes the delivery of therapies to the breast cancer site. These therapies include fulvestrant, immunotherapies, and Chimeric Antigen Receptor T-cell therapies.

Approval for the Edoxifen therapy’s treatment in ovarian cancer treatment

Atossa Therapeutics, Inc. announced on 8th April 2021, that it is focusing on the next stage of progress for oral Endoxifen by allowing an ovarian cancer patient to be treated with the proprietary treatment. The usage of the proprietary oral Endoxifen in the treatment of the patient was approved by U.S Food and Drug Administration. The FDA did this by issuing a letter that expressed “Safe to Proceed” permission for the treatment of ovarian cancer patients through the expanded access pathway. The treatment is going to be monitored in the medical center of the University of Washington under the care of Surgeon-in-Chief, Dr. Barbara Goff.

How was Endoxifen found out to be effective for the patient?

The previous medical history of the cancer patient as stated by Atossa’s CEO and President Steven Quay shows that the patient has recurrent ovarian cancer which was given the tamoxifen. Tamoxifen is given in cases of ovarian cancer and breast cancer as well. However, the patient’s body did not tolerate tamoxifen and thus further treatment and therapy possibilities were investigated. Functional molecular genomic testing was done with the help of 3D tumor organoid cultures that were grown in the lab by extracting the tumor of the ovarian cancer patient

The resulting treatment that was investigated through testing found out that by using a combination of the therapies Alpelisib and Endoxifen, the tumor was responding exceptionally well. Therefore this positive testing is what helped get the FDA’s approval-however the approval is solely restricted to these patients only.

Get the hottest stocks to trade every day before the market opens 100% ‎free. Click here now. 

Now the next step is to prep the patient and follows the progress of the treatment in the patient. Furthermore, Atossa believes that additional clinical studies should be followed for patients with ovarian cancers.

Get The Best Stocks To Trade Every Day!

Join now to get the NewsHeater.com pre-market morning brief 100% free

Must Read

What Explains MOGO Stock Going Up Today?

The Mogo Inc. (NASDAQ: MOGO) stock has gained 5.04% to $8.55 in premarket trading today. Mogo stock finished last trading day at $8.14, down...

Zynga Inc. (ZNGA) stock rises in the Pre-Market: What’s going on?

Zynga Inc. (ZNGA) announced its first-quarter 2021 financial results after which the ZNGA stock happened to be green after underperformance in the last trade....

American Shared Hospital Services (AMS) Stock Continues to Soar Following Unprecedent Volumes Being Traded

American Shared Hospital Services (AMS) stock prices surged by 30.51% as of market close on May 5th, 2021, bringing the price per share up...

James River Group Holdings Ltd. (NASDAQ: JRVR) stock falls during pre-market. Why is it so?

James River Group Holdings Ltd. (NASDAQ: JRVR) stock plunged by 1.67% at last close while the JRVR stock continued decline by 25.74% at last...

Aviat Networks, Inc. (AVNW) Stock Trending Up After Promising Financial Reports for Most Recent Quarter

Aviat Networks, Inc. (AVNW) stock prices were up 3.81% as of market close on May 5th 2021, bringing the price per share up to...

Ambev S.A. (ABEV) Stock Trends Up Following Highly Promising Earnings Call for Q4 2020

Ambev S.A. (ABEV) stock prices were up 10.3943% shortly after the market opened on May 6th, 2021, bringing the price per share up to...

Sally Beauty Holdings (NYSE:SBH) stock surged in the current trading session; here’s why

In the current trading session, Sally Beauty Holdings Inc. (SBH) stock had surged by 19.69% to $24.25 at the time of writing. SBH stock...

Moderna Inc. (NASDAQ: MRNA) stock declines during current market. Let’s figure out why?

Moderna Inc. (NASDAQ: MRNA) stock falls by 5.31% in the current market trading after MRNA has announced its financial results for Q1 2021. Moderna...

Related News

Fastly, Inc. (NYSE: FSLY) stock plunged in the pre-market trading session: here’s why

Fastly, Inc. (NYSE: FSLY), a company specializing to provide real-time content delivery network services, which offers edge cloud platform, edge software development kit (SDK),...

What Is The Reason For GreenBox (GBOX) Stock Rallying In Pre-Market?

In premarket trading hours, GreenBox POS (NASDAQ: GBOX) rose 5.34% to $11.24 on the last check Thursday. GreenBox stock gained 1.81% to close at...

Why Is The HOME Stock Getting Raised In Pre-Hour Trades?

At last check, shares of At Home Group Inc. (NYSE: HOME) were up 14.90 percent to trade at $36.01 in premarket session today. The...

What Caused Nemaura (NMRD) To Rise Today In Premarket Session?

The shares of Nemaura Medical Inc. (NASDAQ: NMRD) were trading 12.12% higher at $12.4 before the bell at last check. Nemaura stock closed the...

Luokung Technology Corp. (LKCO) Stock Surges Amid China-U.S. Economic Tensions

Luokung Technology Corp. (LKCO) stock prices were down by 8.64% as of the market closing on May 5th, 2021, bringing the price per share...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Get The Best Stocks To Trade Every Day!

Join now to get the NewsHeater.com pre-market morning brief 100% free

Get Best Morning Financial Newsletter... 100% Free

Best stocks ideas

Analysts’ Upgrades & Downgrades

Insider Watchlist

Important Earnings

We do not sell or share your information with anyone.

Get The Best Stocks To Trade Every Day!...100% Free

We do not sell or share your information with anyone.

Get The Best Stocks To Trade Every Day!

Join now to get the NewsHeater.com pre-market morning brief 100% free

We do not sell or share your information with anyone.